Vir Biotechnology (VIR) EBT Margin (2018 - 2026)
Vir Biotechnology (VIR) posted EBT Margin of 432844.83% for Q1 2026, down 643940.13% sequentially from 67.21% in Q4 2025, and down 42885574.0% YoY from N/an in Q1 2025.
Vir Biotechnology (VIR) EBT Margin (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported EBT Margin for 9 years, with the latest figure at 432844.83% in Q1 2026.
- Quarterly EBT Margin fell 42885574.0% year-over-year to 432844.83% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 674.79% (up 210098.0% YoY) and the FY2025 annual result came in at 638.56%, up 6639.0% from the prior year.
- EBT Margin fell to 432844.83% in Q1 2026 per VIR's latest filing, from 67.21% in the prior quarter.
- Over five years, EBT Margin peaked at 74.8% in Q1 2022 and troughed at 432844.83% in Q1 2026.
- A 5-year average of 31861.19% and a median of 845.93% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2026: EBT Margin jumped 861301 bps in 2022, then tumbled 42885574 bps in 2026.
- Over 5 years, EBT Margin stood at 306.9% in 2022, then sank by 134 bps to 719.35% in 2023, then fell by 18 bps to 845.93% in 2024, then soared by 92 bps to 67.21% in 2025, then tumbled by 643940 bps to 432844.83% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 432844.83%, 67.21%, and 67905.42% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 33.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.59% |
| Mar 31, 2026 | -432,844.83% |
| Dec 31, 2025 | -67.21% |
| Sep 30, 2025 | -67,905.42% |
| Jun 30, 2025 | -9,125.86% |
| Mar 31, 2025 | -3,989.08% |
| Dec 31, 2024 | -845.93% |
| Sep 30, 2024 | -8,972.27% |
| Jun 30, 2024 | -4,549.27% |
| Mar 31, 2024 | -125.73% |
| Dec 31, 2023 | -719.35% |
| Sep 30, 2023 | -6,313.98% |
| Jun 30, 2023 | -5,204.71% |
| Mar 31, 2023 | -227.44% |
| Dec 31, 2022 | -306.90% |
| Sep 30, 2022 | 58.13% |
| Jun 30, 2022 | -575.26% |
| Mar 31, 2022 | 74.80% |
| Dec 31, 2021 | 67.17% |
| Sep 30, 2021 | 106.90% |